CFTR dysfunction and its specific treatment Source: International Congress 2018 – PG18 Cystic fibrosis: management in adult patients Year: 2018
ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies Source: Eur Respir J, 56 (6) 2000946; 10.1183/13993003.00946-2020 Year: 2020
The effect of current therapeutic modalities on epithelial barrier defects and remodelling Source: International Congress 2014 – Epithelial barrier dysfunction: the link between paediatric and adult respiratory diseases Year: 2014
How organoids helped to discover cystic fibrosis transmembrane conductance regulator (CFTR) therapeutics and predict response to treatment Source: International Congress 2016 – Closing the gap: novel translational research strategies Year: 2016
Measuring CFTR function in respiratory epithelial cell cultures: step to individualize treatments in cystic fibrosis? Source: Virtual Congress 2021 – Monitoring of lung disease and CFTR function in children with cystic fibrosis Year: 2021
Improved CFTR and lung function with VX-770, a novel investigational potentiator of CFTR, in subjects with the G551D-CFTR mutation Source: Annual Congress 2010 - Cystic fibrosis: new targets for therapy and impact of viral infections Year: 2010
Loss of CFTR causes endothelial barrier failure in pneumonia via inhibition of WNK1 and TRPV4 activation Source: International Congress 2017 – From respiratory muscles to acute respiratory failure Year: 2017
Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis Source: Eur Respir Rev 2013; 22: 58-65 Year: 2013
Impaired pulmonary status in cystic fibrosis adults with two mutated MBL-2 alleles Source: Eur Respir J 2004; 24 : 798-804 Year: 2004
Rescue of CFTR function impaired by mutations in exon 15 Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis Year: 2020
Genetic alteration in the mammalian chloride channel CLNS1A alter lung function in children Source: Eur Respir J 2006; 28: Suppl. 50, 476s Year: 2006
Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration Source: Eur Respir J, 59 (2) 2100185; 10.1183/13993003.00185-2021 Year: 2022
The cystic fibrosis airway milieu enhances rescue of F508del in a pre-clinical model Source: Eur Respir J, 52 (6) 1801133; 10.1183/13993003.01133-2018 Year: 2018
The CFTR and EGFR relationship in airway vascular growth, and its importance in cystic fibrosis Source: Eur Respir J 2013; 42: 1438-1440 Year: 2013
Pharmacology and regulation of ENaC function: implication in cystic fibrosis Source: Annual Congress 2009 - Novel regulators of alveolar liquid clearance Year: 2009
Assessing small airway function for early detection of lung function impairment Source: Eur Respir J, 56 (1) 2001946; 10.1183/13993003.01946-2020 Year: 2020
The central role of CFTR in lung disease Source: International Congress 2016 – What can respiratory medicine learn from cystic fibrosis research? Year: 2016
A European regulatory perspective on cystic fibrosis: current treatments, trends in drug development and translational challenges for CFTR modulators Source: Eur Respir Rev, 27 (148) 170124; 10.1183/16000617.0124-2017 Year: 2018
The role of the COPD susceptibility gene FAM13A in barrier function and pro-inflammatory responses of human airway epithelial cells Source: ERS Lung Science Conference 2020 Year: 2020